trending Market Intelligence /marketintelligence/en/news-insights/trending/u5qAoYbljefbnvt5IZUk2g2 content esgSubNav
In This List

Australian regulator approves Endologix's abdominal aortic aneurysm treatment

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Blog

Infographic: The Big Picture 2023 Issuer & Investor Relations Outlook


Australian regulator approves Endologix's abdominal aortic aneurysm treatment

The Australian Therapeutic Goods Administration approved Endologix Inc.'s AFX2 Bifurcated Endograft System for inclusion on the Australian register of therapeutic goods.

The regulator has approved the use of AFX2 for the treatment of abdominal aortic aneurysms.

Endologix CEO John McDermott said the approval in Australia will allow the company to start offering the latest version of the anatomical fixation system to physicians and patients starting in 2017.